Immunome Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
5. Balance sheet components
Property and equipment
Property and equipment consisted of the following (in thousands):
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Lab equipment | $10,580 | $9,501 |
| Construction in progress | 5,548 | 3,297 |
| Leasehold improvements | 4,164 | 1,636 |
| Computer equipment | 502 | 270 |
| Office equipment and furniture and fixtures | 212 | 158 |
| Property and equipment at cost | 21,006 | 14,862 |
| Less accumulated depreciation and amortization | (6,370) | (4,749) |
| Property and equipment, net | $14,636 | $10,113 |
Depreciation and amortization expense was $2.5 million and $1.6 million for the years ended December 31,2025 and 2024, respectively. Construction in progress is not depreciated until the related assets are placed in service. Construction in progress consists primarily of costs related to the build-out office and laboratory facilities.
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Compensation and related benefits | $11,527 | $5,861 |
| Development milestones | 10,000 | 6,150 |
| Manufacturing expenses | 9,462 | 6,544 |
| Clinical development expenses | 7,036 | 6,581 |
| Operating lease liabilities, current portion | — | 63 |
| Other | 3,626 | 7,978 |
| Total accrued expenses and other current liabilities | $41,651 | $33,177 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.